The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
Eli Lilly is leveraging artificial intelligence to find its next big breakthrough after the GLP-1 boom transformed diabetes and obesity treatment. With rivals like Novo Nordisk in hot pursuit, Lilly's AI investments promise faster drug discovery and smarter clinical trials. This strategic shift could diversify revenue and bring new options to patients sooner.
Novo Nordisk has launched a new subscription program for Wegovy, promising up to $1,200 in yearly savings on injections to help patients maintain access to this GLP-1 obesity drug. With plans starting at $249 per month for 12 months, it targets self-pay users facing cost uncertainty. But eligibility limits mean it's not for everyone—here's what you need to know.
Hims & Hers shares surged Monday after HHS Secretary Robert F. Kennedy Jr. expressed urgency on the Joe Rogan Experience to make 14 peptides more accessible. He highlighted FDA's review of the science behind these GLP-1 active ingredients for diabetes and weight loss. This could signal easing regulatory headwinds for telehealth providers like Hims.
Five years post-COVID peak, America's trust in the CDC has plummeted amid testing delays, poor communication, and policy missteps. Experts outline six critical reforms for the next director to refocus the agency on infectious threats while addressing chronic diseases. Restoring credibility is essential before the next pandemic strikes.
West Pharmaceuticals is expanding its Dublin manufacturing site, adding 330 high-skilled jobs to meet surging demand for drug delivery solutions in diabetes and obesity treatments. The 165,000 square foot facility upgrade focuses on containment and delivery systems for injectables, including next-generation GLP-1 therapies like those used in semaglutide drugs. This move strengthens Ireland's role in global metabolic health supply chains.
Boston-based Kailera Therapeutics is gearing up for an IPO to fuel its obesity drug pipeline, including Phase III GLP-1/GIP agonist ribupatide. Backed by $400M Series A and $600M Series B, the company eyes superior profiles versus blockbusters like Zepbound. Despite $368.7M deficits, topline data looms large.
Research shows 80-90% of health is shaped beyond the doctor's office, with food as a powerful yet underused medicine. At a Dallas panel, experts revealed how nutritious meals helped HIV patients live longer and can combat heart disease killing 2,500 daily. Discover strategies for all ages, including GLP-1 users.
India's GLP-1 market surges with over 50 cheap generics from firms like Dr. Reddy's and Sun Pharma, priced as low as US$14/month post-patent expiry. Yet experts flag nutrition risks as appetite suppression drives reliance on substandard supplements failing label claims by 20-40%. Discover the quality crisis threatening diabetic and obese populations.
In a coordinated crackdown, the Saudi Ministry of Health detained several gym trainers for promoting and selling unregistered weight loss medications, hormonal drugs, and peptide substances like Retatrutide. Authorities raided a supply warehouse after social media monitoring. Learn the risks and how to protect yourself.
